Natalia Magdalena Krzyżanowska

Ms. Natalia Magdalena Krzyżanowska

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NKNatalia Magdalena Krzyżanowska
Natalia Magdalena Krzyżanowska
KWKamila Wojas
Kamila Wojas
Janusz MilanowskiJanusz Milanowski
Janusz Milanowski
PKPawel Krawczyk
Pawel Krawczyk
Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monotherapy are anti-PD-1 and anti-PD-L1 antibodies. The effectiveness of both groups of antibodies has been proven in many clinical trials, which have translated into positive immunotherapeutic registrations for cancer patients worldwide. These antibodies are generally well tolerated, and certain patients achieve durable responses. However, given the resistance of some patients to this form of therapy, along with its other drawbacks, such as adverse events, alternatives are constantly being sought. Specifically, new drugs targeting already known molecules are being tested, and new potential targets are being explored. The aim of this paper is to provide an overview of the latest developments in this area.

29 March 2024 in Molecules
Verified
Journal Article
Open access
PDF file
PLPatryk Lasek
Patryk Lasek
UKUrszula Kosikowska
Urszula Kosikowska
PKPrzemysław Kołodziej
Przemysław Kołodziej
GKGrażyna Kubiak-Tomaszewska
Grażyna Kubiak-Tomaszewska
NKNatalia Magdalena Krzyżanowska
Natalia Magdalena Krzyżanowska
Monika WujecMonika Wujec
Monika Wujec
Over the years, several new medicinal substances have been introduced for the treatment of diseases caused by bacteria and parasites. Unfortunately, due to the production of numerous defense mechanisms by microorganisms and parasites, they still pose a serious threat to humanity around the world. Therefore, laboratories all over the world are still working on finding new, effective methods of pharmacotherapy. This research work aimed to synthesize new compounds derived from 3-trifluoromethylbenzoic acid hydrazide and to determine their biological activity. The first stage of the research was to obtain seven new compounds, including six linear compounds and one derivative of 1,2,4-triazole. The PASS software was used to estimate the potential probabilities of biological activity of the newly obtained derivatives. Next, studies were carried out to determine the nematocidal potential of the compounds with the use of nematodes of the genus Rhabditis sp. and antibacterial activity using the ACCT standard strains. To determine the lack of cytotoxicity, tests were performed on two cell lines. Additionally, an antioxidant activity test was performed due to the importance of scavenging free radicals in infections with pathogenic microorganisms. The conducted research proved the anthelmintic and antibacterial potential of the newly obtained compounds. The most effective were two compounds with a 3-chlorophenyl substituent, both linear and cyclic derivatives. They demonstrated higher efficacy than the drugs used in treatment.

12 May 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
NGNatalia Galant
Natalia Galant
MNMarcin Nicoś
Marcin Nicoś
MKMaryna Khalavka
Maryna Khalavka
NKNatalia Magdalena Krzyżanowska
Natalia Magdalena Krzyżanowska
ICIzabela Chmielewska
Izabela Chmielewska
JDJoanna Depciuch
Joanna Depciuch
The direction of anticancer therapies has changed in recent years, including the increasing use of immunotherapy. However, around 50 % of non-small-cell lung cancer (NSCLC) patients do not respond to immunotherapy. Therefore, it is important to find a marker that will allow us to assess whether it will be effective. In the presented work, Fourier Transform InfraRed (FTIR) spectroscopy was used for the first time to predict the response rate of NSCLC. Plasma before treatment and after the initial assessment of response were measured by FTIR and analyzed by Principal Component Analysis (PCA), Receiver Operating Characteristic (ROC) and decision tree algorithm to find wavenumbers, which could be used for differentiation of long-lasting (L) and short-lasting responding (S) patients received immunotherapy or chemoimmunotherapy. The results obtained showed that the FTIR range from 800 cm-1 to 1800 cm-1 distinguished between L and S patients before treatment and after the first response evaluation. Area Under Curve ROC (AUC-ROC) confirmed a high probability of this differentiation. With the usage of a band around 1750 cm-1, it was possible to differentiate L and S patients before and after the first response evaluation. It was also noticed that an additional band at 1539 cm-1 played an important role in distinguishing L and S patients, while after the first response evaluation, the second band was placed at 1080 cm-1. Significantly, all of these bands correlated with biochemical data. Consequently, the results demonstrated that liquid biopsy-based FTIR spectroscopy can predict the response of NSCLC patients to immunotherapy or chemoimmunotherapy.

15 January 2025 in Oncology in Clinical Practice
Verified
Journal Article
Open access
PDF file
NKNatalia Magdalena Krzyżanowska
Natalia Magdalena Krzyżanowska
Immunotherapy is currently one of the most important treatment options for patients with various cancers. It is predominantly based on immune checkpoint inhibitors (ICIs), which are supposed to reverse immune suppression caused by interactions of negative immune checkpoints with their ligands. Cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), and its ligand, programmed death ligand 1 (PD-L1) are the checkpoints targeted by antibodies registered in various types of cancer to enable effective anti-cancer immune response. Despite numerous possibilities, other molecules belonging to immune checkpoints — T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT), are being extensively researched, mainly due to their role in cancer progression and resistance to immunotherapy. Recently, the first antibody against LAG-3 — relatlimab has been registered in melanoma, and many others are tested in the final stages of clinical trials. Thus, understanding their intricate functions and developing strategies to use them can create opportunities to apply immunotherapy in cancer treatment. This article describes their characteristics and potential role in solid-tumor treatment with TIM-3, LAG-3, and TIGIT molecules, which have been connected to tumor progression, poor survival, and poor prognosis in many tumor types. Keywords: TIM-3 LAG-3 TIGIT immunotherapy negative immune checkpoints solid tumors

29 June 2023 in Oncology in Clinical Practice
Verified
Journal Article
Open access
PDF file
NKNatalia Magdalena Krzyżanowska
Natalia Magdalena Krzyżanowska
PKPaweł Krawczyk
Paweł Krawczyk
ICIzabela Chmielewska
Izabela Chmielewska
TJTomasz Jankowski
Tomasz Jankowski
KWKamila Wojas-Krawczyk
Kamila Wojas-Krawczyk
JMJanusz Milanowski
Janusz Milanowski
Immunotherapy is a groundbreaking treatment method when it comes to cancer, and this includes non-small-cell lung cancer (NSCLC). In NSCLC patients, immunotherapy is used in a form of immune checkpoint inhibitors (ICIs), and depending on the proportion of tumor cells with programmed death ligand 1 (PD-L1) expression on them, it can be administered either in monotherapy (≥ 50%) or in combination with chemotherapy (< 50%). In this article, we would like to present a case of a female patient with Kirsten Rat Sarcoma Virus (KRAS)-mutated lung adenocarcinoma who was responding to chemoimmunotherapy for a long time despite the presence of co-mutation in the Serine/Threonine Kinase 11 (STK11) gene, known to worsen immunotherapy outcomes. In this patient, another mutation was found – in the nibrin (NBN) gene, which is of uncertain relevance, but it presumably could be connected to a better outcome as it encodes proteins involved in DNA repair. Deficiency in DNA repair may be marked by homologous recombination deficiency (HRD), and there already exists some evidence of better immunotherapy efficacy in patients with HRD. Considering the above, further investigation and thorough genetic diagnostics in NSCLC patients are required to fully understand the background of immunotherapy response. Immunotherapy is a groundbreaking treatment method when it comes to cancer, and this includes non-small-cell lung cancer (NSCLC). In NSCLC patients, immunotherapy is used in a form of immune checkpoint inhibitors (ICIs), and depending on the proportion of tumor cells with programmed death ligand 1 (PD-L1) expression on them, it can be administered either in monotherapy (≥ 50%) or in combination with chemotherapy (< 50%). In this article, we would like to present a case of a female patient with Kirsten Rat Sarcoma Virus (KRAS)-mutated lung adenocarcinoma who was responding to chemoimmunotherapy for a long time despite the presence of co-mutation in the Serine/Threonine Kinase 11 (STK11) gene, known to worsen immunotherapy outcomes. In this patient, another mutation was found – in the nibrin (NBN) gene, which is of uncertain relevance, but it presumably could be connected to a better outcome as it encodes proteins involved in DNA repair. Deficiency in DNA repair may be marked by homologous recombination deficiency (HRD), and there already exists some evidence of better immunotherapy efficacy in patients with HRD. Considering the above, further investigation and thorough genetic diagnostics in NSCLC patients are required to fully understand the background of immunotherapy response.

28 October 2025 in Oncology in Clinical Practice
Verified
Journal Article
Open access
PDF file
NKNatalia Magdalena Krzyżanowska
Natalia Magdalena Krzyżanowska
PKPaweł Krawczyk
Paweł Krawczyk
KWKamila Wojas-Krawczyk
Kamila Wojas-Krawczyk
ŁGŁukasz Gajek
Łukasz Gajek
AOAdrian Obara
Adrian Obara
Genes that encode proteins involved in DNA repair have been extensively studied in relation to tumorigenesis and cancer treatment. Many germline variants that significantly increase the risk of cancer development have been identified, with PALB2 and CHEK2 being among those genes of interest, as they influence the likelihood of cancer occurrence, such as breast and prostate cancer. This study presents a family with multiple cancer cases carrying germline variants in PALB2 (c.172_175del, p.Gln60Argfs) and CHEK2 (c.470T>C, p.Ile157Thr). In the individual in whom the variants were first discovered, early-onset breast cancer occurred. While one variant is considered pathogenic, the other remains questionable. This paper aims to describe the family’s characteristics and discuss the genetic alterations that contribute to tumor development among its members. Keywords: PALB2 CHEK2 germline mutation inherited cancer breast cancer